<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>COMETRIQ- cabozantinib 
			 </strong><br><strong>COMETRIQ- cabozantinib s-malate capsule </strong><br>Exelixis, Inc.<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use COMETRIQ safely and effectively. See full prescribing information for COMETRIQ.<br>COMETRIQ<span class="Sup">™</span> (cabozantinib) capsules, for oral use<br>Initial U.S. Approval: 2012</div>
<div class="Warning"><div>
<h1 class="Warning"><span class="Bold">WARNING: PERFORATIONS AND <span class="product-label-link" type="condition" conceptid="4043006" conceptname="Fistula">FISTULAS</span>, and<br><span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">HEMORRHAGE</span></span></h1>
<h1 class="Warning"><span class="Bold Italics">See full prescribing information for complete boxed warning.</span></h1>
<ul>
<li><span class="Bold">Perforations and <span class="product-label-link" type="condition" conceptid="4043006" conceptname="Fistula">Fistulas</span>: <span class="product-label-link" type="condition" conceptid="4202064" conceptname="Gastrointestinal perforation">Gastrointestinal perforations</span> occurred in 3% and <span class="product-label-link" type="condition" conceptid="4043006" conceptname="Fistula">fistula</span> formation in 1% of COMETRIQ-treated patients. Discontinue COMETRIQ in patients with perforation or <span class="product-label-link" type="condition" conceptid="4043006" conceptname="Fistula">fistula</span>. (<a href="#s5.1">5.1</a>)</span></li>
<li><span class="Bold"><span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Hemorrhage</span>: Severe, sometimes fatal, <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span> including <span class="product-label-link" type="condition" conceptid="261687" conceptname="Hemoptysis">hemoptysis</span> and <span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">gastrointestinal hemorrhage</span> occurred in 3% of COMETRIQ-treated patients. Monitor patients for signs and symptoms of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>. Do not administer COMETRIQ to patients with severe <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span>. (<a href="#s5.2">5.2</a>)</span></li>
</ul>
</div></div>
<div></div>
<div class="Warning"><div>
<h1 class="Warning"><span class="Bold">WARNING: PERFORATIONS AND <span class="product-label-link" type="condition" conceptid="4043006" conceptname="Fistula">FISTULAS</span>, and<br><span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">HEMORRHAGE</span></span></h1>
<h1 class="Warning"><span class="Bold Italics">See full prescribing information for complete boxed warning.</span></h1>
<ul>
<li><span class="Bold">Perforations and <span class="product-label-link" type="condition" conceptid="4043006" conceptname="Fistula">Fistulas</span>: <span class="product-label-link" type="condition" conceptid="4202064" conceptname="Gastrointestinal perforation">Gastrointestinal perforations</span> occurred in 3% and <span class="product-label-link" type="condition" conceptid="4043006" conceptname="Fistula">fistula</span> formation in 1% of COMETRIQ-treated patients. Discontinue COMETRIQ in patients with perforation or <span class="product-label-link" type="condition" conceptid="4043006" conceptname="Fistula">fistula</span>. (<a href="#s5.1">5.1</a>)</span></li>
<li><span class="Bold"><span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Hemorrhage</span>: Severe, sometimes fatal, <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span> including <span class="product-label-link" type="condition" conceptid="261687" conceptname="Hemoptysis">hemoptysis</span> and <span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">gastrointestinal hemorrhage</span> occurred in 3% of COMETRIQ-treated patients. Monitor patients for signs and symptoms of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>. Do not administer COMETRIQ to patients with severe <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span>. (<a href="#s5.2">5.2</a>)</span></li>
</ul>
</div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div><p class="Highlighta">COMETRIQ is a kinase inhibitor indicated for the treatment of patients with progressive, metastatic medullary thyroid cancer (MTC). (<a href="#s1">1</a>) </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div><ul>
<li>Recommended Dose: 140 mg orally, once daily. (<a href="#s2.1">2.1</a>)</li>
<li>Instruct patients not to eat for at least 2 hours before and at least 1 hour after taking COMETRIQ. (<a href="#s2.1">2.1</a>)</li>
</ul></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><p class="Highlighta">20 mg and 80 mg capsules. (<a href="#s3">3</a>) </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><p class="Highlighta">None. (<a href="#s4">4</a>) </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul>
<li>Thrombotic Events: Discontinue COMETRIQ for <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, <span class="product-label-link" type="condition" conceptid="443454" conceptname="Cerebral infarction">cerebral infarction</span>, or other serious arterial <span class="product-label-link" type="condition" conceptid="4185607" conceptname="Embolism">thromboembolic events</span>. (<a href="#s5.3">5.3</a>)</li>
<li><span class="product-label-link" type="condition" conceptid="4177613" conceptname="Wound pain">Wound Complications</span>: Withhold COMETRIQ for dehiscence or complications requiring medical intervention. (<a href="#s5.4">5.4</a>)</li>
<li><span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span>: Monitor blood pressure regularly. Discontinue COMETRIQ for <span class="product-label-link" type="condition" conceptid="312938" conceptname="Hypertensive encephalopathy">hypertensive crisis</span>. (<a href="#s5.5">5.5</a>)</li>
<li><span class="product-label-link" type="condition" conceptid="77650" conceptname="Aseptic necrosis of bone">Osteonecrosis</span> of the jaw: Discontinue COMETRIQ. (<a href="#s5.6">5.6</a>).</li>
<li>Palmar-plantar Erythrodysesthesia syndrome (PPES): Interrupt COMETRIQ, decrease dose. (<a href="#s5.7">5.7</a>)</li>
<li><span class="product-label-link" type="condition" conceptid="75650" conceptname="Proteinuria">Proteinuria</span>: Monitor urine protein. Discontinue for <span class="product-label-link" type="condition" conceptid="195314" conceptname="Nephrotic syndrome">nephrotic syndrome</span>. (<a href="#s5.8">5.8</a>)</li>
<li><span class="product-label-link" type="condition" conceptid="42872891" conceptname="Posterior reversible encephalopathy syndrome">Reversible posterior leukoencephalopathy syndrome</span> (RPLS): Discontinue COMETRIQ. (<a href="#s5.9">5.9</a>)</li>
<li>Embryofetal toxicity: Can cause fetal harm. Advise women of potential risk to a fetus. (<a href="#s5.11">5.11</a>, <a href="#s8.1">8.1</a>)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">The most commonly reported adverse drug reactions (≥25%) are <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="138455" conceptname="Stomatitis">stomatitis</span>, palmar-plantar erythrodysesthesia syndrome (PPES), decreased weight, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">decreased appetite</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="4010025" conceptname="Painful mouth">oral pain</span>, <span class="product-label-link" type="condition" conceptid="4242607" conceptname="Hair discoloration">hair color changes</span>, <span class="product-label-link" type="condition" conceptid="436235" conceptname="Taste sense altered">dysgeusia</span>, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, and <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>. The most common laboratory abnormalities (≥25%) are increased AST, increased ALT, <span class="product-label-link" type="condition" conceptid="441541" conceptname="Lymphocytopenia">lymphopenia</span>, increased alkaline phosphatase, <span class="product-label-link" type="condition" conceptid="435510" conceptname="Hypocalcemia">hypocalcemia</span>, <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, <span class="product-label-link" type="condition" conceptid="4177973" conceptname="Hypophosphatemia">hypophosphatemia</span>, and <span class="product-label-link" type="condition" conceptid="4032334" conceptname="Hyperbilirubinemia">hyperbilirubinemia</span>. (<a href="#s6.1">6.1</a>) </p>
<br><p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Exelixis, Inc. at 1-855-500-3935 or FDA at 1-800-FDA-1088 or </span><span class="Italics"><a href="#_Ref">www.fda.gov/medwatch.</a></span> </p>
</div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><p class="Highlighta">Cabozantinib is a CYP3A4 substrate (<a href="#s5.10">5.10</a>, <a href="#s7.1">7.1</a>, <a href="#s7.2">7.2</a>). Coadministration of strong CYP3A4 inhibitors can increase cabozantinib exposure (<a href="#s2.1">2.1</a>, <a href="#s5.10">5.10</a>, <a href="#s7.1">7.1</a>). Chronic co-administration of strong CYP3A4 inducers can reduce cabozantinib exposure. (<a href="#s2.1">2.1</a>, <a href="#s5.10">5.10</a>, <a href="#s7.2">7.2</a>). </p></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div><div></div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling.</p>
<p class="HighlightsRevision">Revised: 5/2012</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">WARNING: PERFORATIONS AND <span class="product-label-link" type="condition" conceptid="4043006" conceptname="Fistula">FISTULAS</span>, and <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">HEMORRHAGE</span></a></h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE</a></h1>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc">2.1 Recommended Dose</a></h2>
<h2><a href="#section-2.2" class="toc">2.2 Dosage Adjustments</a></h2>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1 Perforations and <span class="product-label-link" type="condition" conceptid="4043006" conceptname="Fistula">Fistulas</span></a></h2>
<h2><a href="#section-5.2" class="toc">5.2 <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Hemorrhage</span></a></h2>
<h2><a href="#section-5.3" class="toc">5.3 Thrombotic Events</a></h2>
<h2><a href="#section-5.4" class="toc">5.4 <span class="product-label-link" type="condition" conceptid="4177613" conceptname="Wound pain">Wound Complications</span></a></h2>
<h2><a href="#section-5.5" class="toc">5.5 <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span></a></h2>
<h2><a href="#section-5.6" class="toc">5.6 <span class="product-label-link" type="condition" conceptid="77650" conceptname="Aseptic necrosis of bone">Osteonecrosis</span> of the Jaw</a></h2>
<h2><a href="#section-5.7" class="toc">5.7 Palmar-Plantar Erythrodysesthesia Syndrome</a></h2>
<h2><a href="#section-5.8" class="toc">5.8 <span class="product-label-link" type="condition" conceptid="75650" conceptname="Proteinuria">Proteinuria</span></a></h2>
<h2><a href="#section-5.9" class="toc">5.9 <span class="product-label-link" type="condition" conceptid="42872891" conceptname="Posterior reversible encephalopathy syndrome">Reversible Posterior Leukoencephalopathy Syndrome</span></a></h2>
<h2><a href="#section-5.10" class="toc">5.10 Drug Interactions</a></h2>
<h2><a href="#section-5.11" class="toc">5.11 <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></a></h2>
<h2><a href="#section-5.12" class="toc">5.12 Embryo-fetal Toxicity</a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1 Clinical Trial Experience</a></h2>
<h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS</a></h1>
<h2><a href="#section-7.1" class="toc">7.1 Effect of CYP3A4 Inhibitors</a></h2>
<h2><a href="#section-7.2" class="toc">7.2 Effect of CYP3A4 Inducers</a></h2>
<h1><a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.2 Nursing Mothers</a></h2>
<h2><a href="#section-8.3" class="toc">8.3 Pediatric Use</a></h2>
<h2><a href="#section-8.4" class="toc">8.4 Geriatric Use</a></h2>
<h2><a href="#section-8.5" class="toc">8.5 Females and Males of Reproductive Potential</a></h2>
<h2><a href="#section-8.6" class="toc">8.6 <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></a></h2>
<h2><a href="#section-8.7" class="toc">8.7 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></a></h2>
<h1><a href="#section-9" class="toc">10 OVERDOSAGE</a></h1>
<h1><a href="#section-10" class="toc">11 DESCRIPTION</a></h1>
<h1><a href="#section-11" class="toc">12 CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">12.1 Mechanism of Action</a></h2>
<h2><a href="#section-11.2" class="toc">12.3 Pharmacokinetics</a></h2>
<h2><a href="#section-11.3" class="toc">12.6 Cardiac Electrophysiology</a></h2>
<h1><a href="#section-12" class="toc">13 NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h1><a href="#section-13" class="toc">14 CLINICAL STUDIES</a></h1>
<h1><a href="#section-14" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h1><a href="#section-15" class="toc">17 PATIENT COUNSELING INFORMATION</a></h1>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Warning">
<a name="s0"></a><a name="section-1"></a><p></p>
<h1>WARNING: PERFORATIONS AND <span class="product-label-link" type="condition" conceptid="4043006" conceptname="Fistula">FISTULAS</span>, and <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">HEMORRHAGE</span></h1>
<p class="First"><span class="Bold">Perforations and <span class="product-label-link" type="condition" conceptid="4043006" conceptname="Fistula">fistulas</span>: <span class="product-label-link" type="condition" conceptid="4202064" conceptname="Gastrointestinal perforation">Gastrointestinal perforations</span> occurred in 3% and <span class="product-label-link" type="condition" conceptid="4043006" conceptname="Fistula">fistula</span> formation in 1% of COMETRIQ™-treated patients. Discontinue COMETRIQ for perforation or for <span class="product-label-link" type="condition" conceptid="4043006" conceptname="Fistula">fistula</span> formation [See </span><span class="Bold Italics"><a href="#s5.1">Warnings and Precautions</a></span><span class="Bold"> (<a href="#s5.1">5.1</a>)].</span></p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Hemorrhage</span>: Severe, sometimes fatal, <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span> including <span class="product-label-link" type="condition" conceptid="261687" conceptname="Hemoptysis">hemoptysis</span> and <span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">gastrointestinal hemorrhage</span> occurred in 3% of COMETRIQ-treated patients. Monitor patients for signs and symptoms of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>. Do not administer COMETRIQ to patients with severe <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span> [See </span><span class="Bold Italics"><a href="#s5.2">Warnings and Precautions</a></span><span class="Bold"> (<a href="#s5.2">5.2</a>)].</span></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="s1"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE</h1>
<p class="First">COMETRIQ is indicated for the treatment of patients with progressive, metastatic medullary thyroid cancer (MTC).</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="s2"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s2.1"></a><a name="section-2.1"></a><p></p>
<h2>2.1 Recommended Dose</h2>
<p class="First">The recommended daily dose of COMETRIQ is 140 mg (one 80-mg and three 20-mg capsules). Do not administer COMETRIQ with food. Instruct patients not to eat for at least 2 hours before and at least 1 hour after taking COMETRIQ. Continue treatment until disease progression or unacceptable toxicity occurs.</p>
<p>Swallow COMETRIQ capsules whole. Do not open COMETRIQ capsules.</p>
<p>Do not take a missed dose within 12 hours of the next dose.</p>
<p>Do not ingest foods (e.g., grapefruit, grapefruit juice) or nutritional supplements that are known to inhibit cytochrome P450 during COMETRIQ treatment.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s2.2"></a><a name="section-2.2"></a><p></p>
<h2>2.2 Dosage Adjustments</h2>
<p class="First"><span class="Italics">For Adverse Reactions</span></p>
<p>Withhold COMETRIQ for NCI CTCAE Grade 4 hematologic adverse reactions, Grade 3 or greater non-hematologic adverse reactions or intolerable Grade 2 adverse reactions.</p>
<p>Upon resolution/improvement of the adverse reaction (i.e., return to baseline or resolution to Grade 1), reduce the dose as follows:</p>
<ul>
<li>If previously receiving 140 mg daily dose, resume treatment at 100 mg daily (one 80-mg and one 20-mg capsule)</li>
<li>If previously receiving 100 mg daily dose, resume treatment at 60 mg daily (three 20-mg capsules)</li>
<li>If previously receiving 60 mg daily dose, resume at 60 mg if tolerated, otherwise, discontinue COMETRIQ</li>
</ul>
<p>Permanently discontinue COMETRIQ for any of the following:</p>
<ul>
<li>development of visceral perforation or <span class="product-label-link" type="condition" conceptid="4043006" conceptname="Fistula">fistula</span> formation</li>
<li>severe <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span></li>
<li>serious arterial <span class="product-label-link" type="condition" conceptid="4185607" conceptname="Embolism">thromboembolic event</span> (e.g., <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, <span class="product-label-link" type="condition" conceptid="443454" conceptname="Cerebral infarction">cerebral infarction</span>)</li>
<li><span class="product-label-link" type="condition" conceptid="195314" conceptname="Nephrotic syndrome">nephrotic syndrome</span></li>
<li><span class="product-label-link" type="condition" conceptid="4289933" conceptname="Malignant hypertension">malignant hypertension</span>, <span class="product-label-link" type="condition" conceptid="312938" conceptname="Hypertensive encephalopathy">hypertensive crisis</span>, persistent <span class="product-label-link" type="condition" conceptid="4269635" conceptname="Hypertensive episode">uncontrolled hypertension</span> despite optimal medical management</li>
<li><span class="product-label-link" type="condition" conceptid="77650" conceptname="Aseptic necrosis of bone">osteonecrosis</span> of the jaw</li>
<li><span class="product-label-link" type="condition" conceptid="42872891" conceptname="Posterior reversible encephalopathy syndrome">reversible posterior leukoencephalopathy syndrome</span></li>
</ul>
<p><span class="Italics">In Patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></span></p>
<p>COMETRIQ is not recommended for use in patients with moderate and severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> <span class="Italics">[see <a href="#s5.11">Warnings and Precautions</a> (<a href="#s5.11">5.11</a>) and <a href="#s8.6">Use in Specific Populations</a> (<a href="#s8.6">8.6</a>)].</span></p>
<p><span class="Italics">In Patients Taking CYP3A4 Inhibitors</span></p>
<p>Avoid the use of concomitant strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, nefazodone, saquinavir, telithromycin, ritonavir, indinavir, nelfinavir, voriconazole) in patients receiving COMETRIQ <span class="Italics">[see <a href="#s5.10">Warnings and Precautions</a> (<a href="#s5.10">5.10</a>) and <a href="#s7.1">Drug Interactions</a><a href="#s7.1">7.1</a>)].</span></p>
<p>For patients who require treatment with a strong CYP3A4 inhibitor, reduce the daily COMETRIQ dose by 40 mg (for example, from 140 mg to 100 mg daily or from 100 mg to 60 mg daily). Resume the dose that was used prior to initiating the CYP3A4 inhibitor 2 to 3 days after discontinuation of the strong inhibitor.</p>
<p><span class="Italics">In Patients Taking Strong CYP3A4 Inducers</span></p>
<p>Avoid the chronic use of concomitant strong CYP3A4 inducers (e.g., phenytoin, carbamazepine, rifampin, rifabutin, rifapentine, phenobarbital) if alternative therapy is available <span class="Italics">[see <a href="#s5.10">Warnings and Precautions</a> (<a href="#s5.10">5.10</a>) and <a href="#s7.2">Drug Interactions</a> (<a href="#s7.2">7.2</a>)].</span></p>
<p>Do not ingest foods or nutritional supplements (e.g., St. John’s Wort (Hypericum perforatum)) that are known to induce cytochrome P450 activity.</p>
<p>For patients who require treatment with a strong CYP3A4 inducer, increase the daily COMETRIQ dose by 40 mg (for example, from 140 mg to 180 mg daily or from 100 mg to 140 mg daily) as tolerated. Resume the dose that was used prior to initiating the CYP3A4 inducer 2 to 3 days after discontinuation of the strong inducer. The daily dose of COMETRIQ should not exceed 180 mg.</p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="s3"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS</h1>
<p class="First">COMETRIQ 20-mg gelatin capsules are grey with "XL184 20mg" printed in black on the body of the capsule.</p>
<p>COMETRIQ 80-mg gelatin capsules are Swedish orange with "XL184 80mg" printed in black on the body of the capsule.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="s4"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS</h1>
<p class="First">None</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="s5"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s5.1"></a><a name="section-5.1"></a><p></p>
<h2>5.1 Perforations and <span class="product-label-link" type="condition" conceptid="4043006" conceptname="Fistula">Fistulas</span></h2>
<p class="First">Gastrointestinal (GI) perforations and <span class="product-label-link" type="condition" conceptid="4043006" conceptname="Fistula">fistulas</span> were reported in 3% and 1% of COMETRIQ-treated patients, respectively. All were serious and one GI <span class="product-label-link" type="condition" conceptid="4043006" conceptname="Fistula">fistula</span> was fatal (&lt; 1%). Non-GI <span class="product-label-link" type="condition" conceptid="4043006" conceptname="Fistula">fistulas</span> including tracheal/esophageal were reported in 4% of COMETRIQ-treated patients. Two (1%) of these were fatal.</p>
<p>Monitor patients for symptoms of perforations and <span class="product-label-link" type="condition" conceptid="4043006" conceptname="Fistula">fistulas</span>. Discontinue COMETRIQ in patients who experience a perforation or a <span class="product-label-link" type="condition" conceptid="4043006" conceptname="Fistula">fistula</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s5.2"></a><a name="section-5.2"></a><p></p>
<h2>5.2 <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Hemorrhage</span></h2>
<p class="First">Serious and sometimes fatal <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span> occurred with COMETRIQ. The incidence of Grade ≥3 hemorrhagic events was higher in COMETRIQ-treated patients compared with placebo (3% vs. 1%).</p>
<p>Do not administer COMETRIQ to patients with a recent history of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span> or <span class="product-label-link" type="condition" conceptid="261687" conceptname="Hemoptysis">hemoptysis</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s5.3"></a><a name="section-5.3"></a><p></p>
<h2>5.3 Thrombotic Events</h2>
<p class="First">COMETRIQ treatment results in an increased incidence of thrombotic events (<span class="product-label-link" type="condition" conceptid="318775" conceptname="Venous embolism">venous thromboembolism</span>: 6% vs. 3% and arterial <span class="product-label-link" type="condition" conceptid="4159647" conceptname="Thromboembolic disorder">thromboembolism</span>: 2% vs. 0% in COMETRIQ-treated and placebo-treated patients, respectively).</p>
<p>Discontinue COMETRIQ in patients who develop an <span class="product-label-link" type="condition" conceptid="312327" conceptname="Acute myocardial infarction">acute myocardial infarction</span> or any other clinically significant arterial thromboembolic complication.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s5.4"></a><a name="section-5.4"></a><p></p>
<h2>5.4 <span class="product-label-link" type="condition" conceptid="4177613" conceptname="Wound pain">Wound Complications</span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4177613" conceptname="Wound pain">Wound complications</span> have been reported with COMETRIQ. Stop treatment with COMETRIQ at least 28 days prior to scheduled surgery. Resume COMETRIQ therapy after surgery based on clinical judgment of adequate <span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">wound</span> healing. Withhold COMETRIQ in patients with dehiscence or <span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">wound</span> healing complications requiring medical intervention.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s5.5"></a><a name="section-5.5"></a><p></p>
<h2>5.5 <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span></h2>
<p class="First">COMETRIQ treatment results in an increased incidence of treatment-emergent <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> with Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (modified JNC criteria) stage 1 or 2 <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> identified in 61% in COMETRIQ-treated patients compared with 30% of placebo-treated patients in the randomized trial. Monitor blood pressure prior to initiation and regularly during COMETRIQ treatment. Withhold COMETRIQ for <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> that is not adequately controlled with medical management; when controlled, resume COMETRIQ at a reduced dose. Discontinue COMETRIQ for severe <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> that cannot be controlled with anti-hypertensive therapy.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s5.6"></a><a name="section-5.6"></a><p></p>
<h2>5.6 <span class="product-label-link" type="condition" conceptid="77650" conceptname="Aseptic necrosis of bone">Osteonecrosis</span> of the Jaw</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="77650" conceptname="Aseptic necrosis of bone">Osteonecrosis</span> of the jaw (ONJ) occurred in 1% of COMETRIQ-treated patients. ONJ can manifest as <span class="product-label-link" type="condition" conceptid="4168686" conceptname="Jaw pain">jaw pain</span>, <span class="product-label-link" type="condition" conceptid="141663" conceptname="Osteomyelitis">osteomyelitis</span>, <span class="product-label-link" type="condition" conceptid="4196380" conceptname="Osteitis">osteitis</span>, bone erosion, tooth or <span class="product-label-link" type="condition" conceptid="141608" conceptname="Periodontitis">periodontal infection</span>, <span class="product-label-link" type="condition" conceptid="4099176" conceptname="Toothache">toothache</span>, <span class="product-label-link" type="condition" conceptid="4324848" conceptname="Ulceration of gingivae">gingival ulceration</span> or erosion, persistent <span class="product-label-link" type="condition" conceptid="4168686" conceptname="Jaw pain">jaw pain</span> or slow healing of the mouth or jaw after dental surgery. Perform an oral examination prior to initiation of COMETRIQ and periodically during COMETRIQ therapy. Advise patients regarding good oral hygiene practices. For invasive dental procedures, withhold COMETRIQ treatment for at least 28 days prior to scheduled surgery, if possible.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s5.7"></a><a name="section-5.7"></a><p></p>
<h2>5.7 Palmar-Plantar Erythrodysesthesia Syndrome</h2>
<p class="First">Palmar-plantar erythrodysesthesia syndrome (PPES) occurred in 50% of patients treated with COMETRIQ and was severe (≥ Grade 3) in 13% of patients. Withhold COMETRIQ in patients who develop intolerable Grade 2 PPES or Grade 3-4 PPES until improvement to Grade 1; resume COMETRIQ at a reduced dose.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s5.8"></a><a name="section-5.8"></a><p></p>
<h2>5.8 <span class="product-label-link" type="condition" conceptid="75650" conceptname="Proteinuria">Proteinuria</span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="75650" conceptname="Proteinuria">Proteinuria</span> was observed in 4 (2%) of patients receiving COMETRIQ, including one with <span class="product-label-link" type="condition" conceptid="195314" conceptname="Nephrotic syndrome">nephrotic syndrome</span>, as compared to none of the patients receiving placebo. Monitor urine protein regularly during COMETRIQ treatment. Discontinue COMETRIQ in patients who develop <span class="product-label-link" type="condition" conceptid="195314" conceptname="Nephrotic syndrome">nephrotic syndrome</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s5.9"></a><a name="section-5.9"></a><p></p>
<h2>5.9 <span class="product-label-link" type="condition" conceptid="42872891" conceptname="Posterior reversible encephalopathy syndrome">Reversible Posterior Leukoencephalopathy Syndrome</span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="42872891" conceptname="Posterior reversible encephalopathy syndrome">Reversible Posterior Leukoencephalopathy Syndrome</span> (RPLS), a syndrome of subcortical vasogenic <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> diagnosed by characteristic finding on MRI, occurred in one (&lt;1%) patient. Perform an evaluation for RPLS in any patient presenting with <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="374034" conceptname="Visual disturbance">visual disturbances</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span> or altered mental function. Discontinue COMETRIQ in patients who develop RPLS.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s5.10"></a><a name="section-5.10"></a><p></p>
<h2>5.10 Drug Interactions</h2>
<p class="First">Avoid administration of COMETRIQ with agents that are strong CYP3A4 inducers or inhibitors <span class="Italics">[see <a href="#s2.1">Dosage and Administration</a> (<a href="#s2.1">2.1</a>) and <a href="#s7.1">Drug Interactions</a> (<a href="#s7.1">7.1</a>, <a href="#s7.2">7.2</a>)].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s5.11"></a><a name="section-5.11"></a><p></p>
<h2>5.11 <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></h2>
<p class="First">COMETRIQ is not recommended for use in patients with moderate or severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> [<span class="Italics">see <a href="#s8.6">Use in Specific Populations</a> (<a href="#s8.6">8.6</a>)</span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s5.12"></a><a name="section-5.12"></a><p></p>
<h2>5.12 Embryo-fetal Toxicity</h2>
<p class="First">COMETRIQ can cause fetal harm when administered to a pregnant woman. Cabozantinib was embryolethal in rats at exposures below the recommended human dose, with increased incidences of skeletal variations in rats and visceral variations and malformations in rabbits. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the fetus <span class="Italics">[See <a href="#s8.1">Use in Specific Populations</a> (<a href="#s8.1">8.1</a>)].</span></p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="s6"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS</h1>
<p class="First">The following serious adverse reactions are discussed elsewhere in the label:</p>
<ul>
<li>Perforations and <span class="product-label-link" type="condition" conceptid="4043006" conceptname="Fistula">Fistula</span> [<span class="Italics">see <a href="#s0">Boxed Warning</a>, <a href="#s5.1">Warnings and Precautions</a> (<a href="#s5.1">5.1</a>)</span>]</li>
<li><span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Hemorrhage</span> [<span class="Italics">see <a href="#s0">Boxed Warning</a>, <a href="#s5.2">Warnings and Precautions</a> (<a href="#s5.2">5.2</a>)</span>]</li>
<li><span class="product-label-link" type="condition" conceptid="4185607" conceptname="Embolism">Thromboembolic Events</span> [<span class="Italics">see <a href="#s5.3">Warnings and Precautions</a> (<a href="#s5.3">5.3</a>)</span>]</li>
<li><span class="product-label-link" type="condition" conceptid="4177613" conceptname="Wound pain">Wound Complications</span> [<span class="Italics">see <a href="#s5.4">Warnings and Precautions</a> (<a href="#s5.4">5.4</a>)</span>]</li>
<li><span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span> [<span class="Italics">see <a href="#s5.5">Warnings and Precautions</a> (<a href="#s5.5">5.5</a>)</span>]</li>
<li><span class="product-label-link" type="condition" conceptid="77650" conceptname="Aseptic necrosis of bone">Osteonecrosis</span> of the Jaw [<span class="Italics">see <a href="#s5.6">Warnings and Precautions</a> (<a href="#s5.6">5.6</a>)</span>]</li>
<li>Palmar-plantar erythrodysesthesia syndrome [<span class="Italics">see <a href="#s5.7">Warnings and Precautions</a> (<a href="#s5.7">5.7</a>)</span>]</li>
<li><span class="product-label-link" type="condition" conceptid="75650" conceptname="Proteinuria">Proteinuria</span> [<span class="Italics">see <a href="#s5.8">Warnings and Precautions</a> (<a href="#s5.8">5.8</a>)</span>]</li>
<li><span class="product-label-link" type="condition" conceptid="42872891" conceptname="Posterior reversible encephalopathy syndrome">Reversible Posterior Leukoencephalopathy Syndrome</span> [<span class="Italics">see <a href="#s5.9">Warnings and Precautions</a>
(<a href="#s5.9">5.9</a>)</span>]</li>
</ul>
<div class="Section" data-sectionCode="42229-5">
<a name="s6.1"></a><a name="section-6.1"></a><p></p>
<h2>6.1 Clinical Trial Experience</h2>
<p class="First">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</p>
<p>The safety of COMETRIQ was evaluated in 330 patients with progressive metastatic medullary thyroid cancer randomized to receive 140 mg COMETRIQ (n = 214) or placebo (n = 109) administered daily until disease progression or intolerable toxicity in a randomized, doubleblind, controlled trial. [<span class="Italics">See <a href="#s14">Clinical Studies</a> (<a href="#s14">14)</a></span>.] The data described below reflect a median exposure to COMETRIQ for 204 days. The population exposed to COMETRIQ was 70% male, 90% white, and had a median age of 55 years.</p>
<p>Adverse reactions which occurred in ≥ 25% of COMETRIQ-treated patients occurring more frequently in the COMETRIQ arm with a between-arm difference of ≥ 5% included, in order of decreasing frequency: <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="138455" conceptname="Stomatitis">stomatitis</span>, palmar-plantar erythrodysesthesia syndrome (PPES), decreased weight, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">decreased appetite</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="4010025" conceptname="Painful mouth">oral pain</span>, <span class="product-label-link" type="condition" conceptid="4242607" conceptname="Hair discoloration">hair color changes</span>, <span class="product-label-link" type="condition" conceptid="436235" conceptname="Taste sense altered">dysgeusia</span>, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, and <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>. The most common laboratory abnormalities (&gt;25%) were increased AST, increased ALT, <span class="product-label-link" type="condition" conceptid="441541" conceptname="Lymphocytopenia">lymphopenia</span>, increased ALP, <span class="product-label-link" type="condition" conceptid="435510" conceptname="Hypocalcemia">hypocalcemia</span>, <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, <span class="product-label-link" type="condition" conceptid="4177973" conceptname="Hypophosphatemia">hypophosphatemia</span>, and <span class="product-label-link" type="condition" conceptid="4032334" conceptname="Hyperbilirubinemia">hyperbilirubinemia</span>. Grade 3-4 adverse reactions and laboratory abnormalities which occurred in ≥ 5% of COMETRIQ-treated patients occurring more frequently in the COMETRIQ arm with a between-arm difference of ≥ 2% included, in order of decreasing frequency; <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, PPES, <span class="product-label-link" type="condition" conceptid="441541" conceptname="Lymphocytopenia">lymphopenia</span>, <span class="product-label-link" type="condition" conceptid="435510" conceptname="Hypocalcemia">hypocalcemia</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span>, increased ALT, decreased weight, <span class="product-label-link" type="condition" conceptid="138455" conceptname="Stomatitis">stomatitis</span>, and <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">decreased appetite</span> (see <a href="#t1">Table 1</a>, <a href="#t2">Table 2</a>).</p>
<p>Fatal adverse reactions occurred in 6% of patients receiving COMETRIQ and resulted from <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span>, <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span>, <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">septicemia</span>, <span class="product-label-link" type="condition" conceptid="4043006" conceptname="Fistula">fistulas</span>, <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">cardiac arrest</span>, <span class="product-label-link" type="condition" conceptid="4256228" conceptname="Respiratory failure">respiratory failure</span>, and unspecified <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. Fatal adverse reactions occurred in 5% of patients receiving placebo and resulted from <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">septicemia</span>, <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span>, and general deterioration.</p>
<p>The dose was reduced in 79% of patients receiving COMETRIQ compared to 9% of patients receiving placebo. The median number of dosing delays was one in patients receiving COMETRIQ compared to none in patients receiving placebo. Adverse reactions led to study treatment discontinuation in 16% of patients receiving COMETRIQ and in 8% of patients receiving placebo. The most frequent adverse reactions leading to permanent discontinuation in patients treated with COMETRIQ were: <span class="product-label-link" type="condition" conceptid="435510" conceptname="Hypocalcemia">hypocalcemia</span>, increased lipase, PPES, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>, <span class="product-label-link" type="condition" conceptid="4121300" conceptname="Tracheal fistula">tracheal fistula</span> formation and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>.</p>
<p>Increased levels of thyroid stimulating hormone (TSH) were observed in 57% of patients receiving COMETRIQ after the first dose compared to 19% of patients receiving placebo (regardless of baseline value). Ninety-two percent (92%) of patients on the COMETRIQ arm had a prior thyroidectomy, and 89% were taking thyroid hormone replacement prior to the first dose.</p>
<a name="t1"></a><table width="85%">
<caption><span>Table 1  Per-Patient Incidence of Selected Adverse Reactions in Protocol XL184-301 Occurring at a Higher Incidence in COMETRIQ-Treated Patients [Between Arm Difference of ≥ 5% (All Grades)<a name="footnote-reference-1" href="#footnote-1" class="Sup">*</a> or ≥ 2% (Grades 3-4)]</span></caption>
<col align="left" valign="middle" width="50%">
<col align="center" valign="middle" width="12.5%">
<col align="center" valign="middle" width="12.5%">
<col align="center" valign="middle" width="12.5%">
<col align="center" valign="middle" width="12.5%">
<thead>
<tr class="First">
<th class="Botrule Lrule Rrule" align="left" rowspan="2">   MedDRA System Organ Class/Preferred Terms</th>
<th class="Botrule Lrule Rrule" align="center" colspan="2">COMETRIQ<br> (n=214)</th>
<th class="Botrule Lrule Rrule" align="center" colspan="2">Placebo<br> (n=109)</th>
</tr>
<tr class="Last">
<th class="Botrule Lrule Rrule" align="center">All<br> Grades</th>
<th class="Botrule Lrule Rrule" align="center">Grades<br>  3-4</th>
<th class="Botrule Lrule Rrule" align="center">All<br> Grades</th>
<th class="Botrule Lrule Rrule" align="center">Grades<br> 3-4</th>
</tr>
</thead>
<tfoot><tr><td colspan="5" align="left"><dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">*</a></dt>
<dd>National Cancer Institute Common Terminology Criteria for Adverse Events Version 3.0</dd>
<dt><a name="footnote-2" href="#footnote-reference-2">†</a></dt>
<dd>Includes the following terms: <span class="product-label-link" type="condition" conceptid="138455" conceptname="Stomatitis">stomatitis</span>, <span class="product-label-link" type="condition" conceptid="138463" conceptname="Aphthous ulcer of mouth">aphthous stomatitis</span>, <span class="product-label-link" type="condition" conceptid="4094986" conceptname="Ulcer of mouth">mouth ulceration</span>, <span class="product-label-link" type="condition" conceptid="432661" conceptname="Inflammatory disease of mucous membrane">mucosal inflammation</span></dd>
<dt><a name="footnote-3" href="#footnote-reference-3">‡</a></dt>
<dd>Includes the following terms: <span class="product-label-link" type="condition" conceptid="4010025" conceptname="Painful mouth">oral pain</span>, oropharyngeal <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, <span class="product-label-link" type="condition" conceptid="436147" conceptname="Glossitis">glossitis</span>, <span class="product-label-link" type="condition" conceptid="4150136" conceptname="Discomfort in mouth">burning mouth</span> syndrome, <span class="product-label-link" type="condition" conceptid="441334" conceptname="Glossodynia">glossodynia</span></dd>
<dt><a name="footnote-4" href="#footnote-reference-4">§</a></dt>
<dd>Includes the following terms: <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="193322" conceptname="Right lower quadrant pain">abdominal pain lower</span>, <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">abdominal pain upper</span>, <span class="product-label-link" type="condition" conceptid="200215" conceptname="Abdominal rigidity">abdominal rigidity</span>, <span class="product-label-link" type="condition" conceptid="197981" conceptname="Abdominal tenderness">abdominal tenderness</span>, <span class="product-label-link" type="condition" conceptid="4009391" conceptname="Pain in esophagus">esophageal pain</span></dd>
<dt><a name="footnote-5" href="#footnote-reference-5">¶</a></dt>
<dd>Palmar-plantar erythrodysesthesia syndrome</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First"><td class="Botrule Lrule Rrule" align="left" colspan="5">   <span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">GASTROINTESTINAL DISORDERS</span></td></tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">        <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></td>
<td class="Botrule Rrule" align="center">63</td>
<td class="Botrule Rrule" align="center">16</td>
<td class="Botrule Rrule" align="center">33</td>
<td class="Botrule Rrule" align="center">2</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">        <span class="product-label-link" type="condition" conceptid="138455" conceptname="Stomatitis">Stomatitis</span><a name="footnote-reference-2" href="#footnote-2" class="Sup">†</a>
</td>
<td class="Botrule Rrule" align="center">51</td>
<td class="Botrule Rrule" align="center">5</td>
<td class="Botrule Rrule" align="center">6</td>
<td class="Botrule Rrule" align="center">0</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">        <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></td>
<td class="Botrule Rrule" align="center">43</td>
<td class="Botrule Rrule" align="center">1</td>
<td class="Botrule Rrule" align="center">21</td>
<td class="Botrule Rrule" align="center">0</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">        <span class="product-label-link" type="condition" conceptid="4010025" conceptname="Painful mouth">Oral pain</span><a name="footnote-reference-3" href="#footnote-3" class="Sup">‡</a>
</td>
<td class="Botrule Rrule" align="center">36</td>
<td class="Botrule Rrule" align="center">2</td>
<td class="Botrule Rrule" align="center">6</td>
<td class="Botrule Rrule" align="center">0</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">        <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span></td>
<td class="Botrule Rrule" align="center">27</td>
<td class="Botrule Rrule" align="center">0</td>
<td class="Botrule Rrule" align="center">6</td>
<td class="Botrule Rrule" align="center">0</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">        <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal pain</span><a name="footnote-reference-4" href="#footnote-4" class="Sup">§</a>
</td>
<td class="Botrule Rrule" align="center">27</td>
<td class="Botrule Rrule" align="center">3</td>
<td class="Botrule Rrule" align="center">13</td>
<td class="Botrule Rrule" align="center">1</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">        <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></td>
<td class="Botrule Rrule" align="center">24</td>
<td class="Botrule Rrule" align="center">2</td>
<td class="Botrule Rrule" align="center">2</td>
<td class="Botrule Rrule" align="center">1</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">        <span class="product-label-link" type="condition" conceptid="31317" conceptname="Dysphagia">Dysphagia</span></td>
<td class="Botrule Rrule" align="center">13</td>
<td class="Botrule Rrule" align="center">4</td>
<td class="Botrule Rrule" align="center">6</td>
<td class="Botrule Rrule" align="center">1</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">        <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">Dyspepsia</span></td>
<td class="Botrule Rrule" align="center">11</td>
<td class="Botrule Rrule" align="center">0</td>
<td class="Botrule Rrule" align="center">0</td>
<td class="Botrule Rrule" align="center">0</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">        <span class="product-label-link" type="condition" conceptid="194382" conceptname="External hemorrhoids">Hemorrhoids</span></td>
<td class="Botrule Rrule" align="center">9</td>
<td class="Botrule Rrule" align="center">0</td>
<td class="Botrule Rrule" align="center">3</td>
<td class="Botrule Rrule" align="center">0</td>
</tr>
<tr><td class="Botrule Lrule Rrule" align="left" colspan="5">   GENERAL DISORDERS AND<br>   ADMINISTRATION SITE CONDITIONS</td></tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">        <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span></td>
<td class="Botrule Rrule" align="center">41</td>
<td class="Botrule Rrule" align="center">9</td>
<td class="Botrule Rrule" align="center">28</td>
<td class="Botrule Rrule" align="center">3</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">        <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">Asthenia</span></td>
<td class="Botrule Rrule" align="center">21</td>
<td class="Botrule Rrule" align="center">6</td>
<td class="Botrule Rrule" align="center">15</td>
<td class="Botrule Rrule" align="center">1</td>
</tr>
<tr><td class="Botrule Lrule Rrule" align="left" colspan="5">   INVESTIGATIONS</td></tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">        Decreased weight</td>
<td class="Botrule Rrule" align="center">48</td>
<td class="Botrule Rrule" align="center">5</td>
<td class="Botrule Rrule" align="center">10</td>
<td class="Botrule Rrule" align="center">0</td>
</tr>
<tr><td class="Botrule Lrule Rrule" align="left" colspan="5">   METABOLISM AND NUTRITION DISORDERS</td></tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">        <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">Decreased appetite</span></td>
<td class="Botrule Rrule" align="center">46</td>
<td class="Botrule Rrule" align="center">5</td>
<td class="Botrule Rrule" align="center">16</td>
<td class="Botrule Rrule" align="center">1</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">        <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">Dehydration</span></td>
<td class="Botrule Rrule" align="center">7</td>
<td class="Botrule Rrule" align="center">2</td>
<td class="Botrule Rrule" align="center">2</td>
<td class="Botrule Rrule" align="center">1</td>
</tr>
<tr><td class="Botrule Lrule Rrule" align="left" colspan="5">   MUSCULOSKELETAL AND CONNECTIVE<br>   TISSUE DISORDERS</td></tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">        <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">Arthralgia</span></td>
<td class="Botrule Rrule" align="center">14</td>
<td class="Botrule Rrule" align="center">1</td>
<td class="Botrule Rrule" align="center">7</td>
<td class="Botrule Rrule" align="center">0</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">        <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">Muscle spasms</span></td>
<td class="Botrule Rrule" align="center">12</td>
<td class="Botrule Rrule" align="center">0</td>
<td class="Botrule Rrule" align="center">5</td>
<td class="Botrule Rrule" align="center">0</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">        <span class="product-label-link" type="condition" conceptid="4092930" conceptname="Musculoskeletal chest pain">Musculoskeletal chest pain</span></td>
<td class="Botrule Rrule" align="center">9</td>
<td class="Botrule Rrule" align="center">1</td>
<td class="Botrule Rrule" align="center">4</td>
<td class="Botrule Rrule" align="center">0</td>
</tr>
<tr><td class="Botrule Lrule Rrule" align="left" colspan="5">   <span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">NERVOUS SYSTEM DISORDERS</span></td></tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">        <span class="product-label-link" type="condition" conceptid="436235" conceptname="Taste sense altered">Dysgeusia</span></td>
<td class="Botrule Rrule" align="center">34</td>
<td class="Botrule Rrule" align="center">0</td>
<td class="Botrule Rrule" align="center">6</td>
<td class="Botrule Rrule" align="center">0</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">        <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></td>
<td class="Botrule Rrule" align="center">18</td>
<td class="Botrule Rrule" align="center">0</td>
<td class="Botrule Rrule" align="center">8</td>
<td class="Botrule Rrule" align="center">0</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">        <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span></td>
<td class="Botrule Rrule" align="center">14</td>
<td class="Botrule Rrule" align="center">0</td>
<td class="Botrule Rrule" align="center">7</td>
<td class="Botrule Rrule" align="center">0</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">        <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">Paresthesia</span></td>
<td class="Botrule Rrule" align="center">7</td>
<td class="Botrule Rrule" align="center">0</td>
<td class="Botrule Rrule" align="center">2</td>
<td class="Botrule Rrule" align="center">0</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">        <span class="product-label-link" type="condition" conceptid="4318869" conceptname="Sensory neuropathy">Peripheral sensory neuropathy</span></td>
<td class="Botrule Rrule" align="center">7</td>
<td class="Botrule Rrule" align="center">0</td>
<td class="Botrule Rrule" align="center">0</td>
<td class="Botrule Rrule" align="center">0</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">        <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">Peripheral neuropathy</span></td>
<td class="Botrule Rrule" align="center">5</td>
<td class="Botrule Rrule" align="center">0</td>
<td class="Botrule Rrule" align="center">0</td>
<td class="Botrule Rrule" align="center">0</td>
</tr>
<tr><td class="Botrule Lrule Rrule" align="left" colspan="5">   PSYCHIATRIC DISORDERS</td></tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">        <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">Anxiety</span></td>
<td class="Botrule Rrule" align="center">9</td>
<td class="Botrule Rrule" align="center">0</td>
<td class="Botrule Rrule" align="center">2</td>
<td class="Botrule Rrule" align="center">0</td>
</tr>
<tr><td class="Botrule Lrule Rrule" align="left" colspan="5">   RESPIRATORY, THORACIC AND<br>   <span class="product-label-link" type="condition" conceptid="440142" conceptname="Disorder of mediastinum">MEDIASTINAL DISORDERS</span></td></tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">        <span class="product-label-link" type="condition" conceptid="432730" conceptname="Difficulty speaking">Dysphonia</span></td>
<td class="Botrule Rrule" align="center">20</td>
<td class="Botrule Rrule" align="center">0</td>
<td class="Botrule Rrule" align="center">9</td>
<td class="Botrule Rrule" align="center">0</td>
</tr>
<tr><td class="Botrule Lrule Rrule" align="left" colspan="5">   SKIN AND SUBCUTANEOUS TISSUE<br>   DISORDERS</td></tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">        PPES<a name="footnote-reference-5" href="#footnote-5" class="Sup">¶</a>
</td>
<td class="Botrule Rrule" align="center">50</td>
<td class="Botrule Rrule" align="center">13</td>
<td class="Botrule Rrule" align="center">2</td>
<td class="Botrule Rrule" align="center">0</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">        <span class="product-label-link" type="condition" conceptid="4242607" conceptname="Hair discoloration">Hair color changes</span>/<br>        depigmentation, graying</td>
<td class="Botrule Rrule" align="center">34</td>
<td class="Botrule Rrule" align="center">0</td>
<td class="Botrule Rrule" align="center">1</td>
<td class="Botrule Rrule" align="center">0</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">        <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span></td>
<td class="Botrule Rrule" align="center">19</td>
<td class="Botrule Rrule" align="center">1</td>
<td class="Botrule Rrule" align="center">10</td>
<td class="Botrule Rrule" align="center">0</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">        <span class="product-label-link" type="condition" conceptid="4039266" conceptname="Dry skin">Dry skin</span></td>
<td class="Botrule Rrule" align="center">19</td>
<td class="Botrule Rrule" align="center">0</td>
<td class="Botrule Rrule" align="center">3</td>
<td class="Botrule Rrule" align="center">0</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">        <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">Alopecia</span></td>
<td class="Botrule Rrule" align="center">16</td>
<td class="Botrule Rrule" align="center">0</td>
<td class="Botrule Rrule" align="center">2</td>
<td class="Botrule Rrule" align="center">0</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">        <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">Erythema</span></td>
<td class="Botrule Rrule" align="center">11</td>
<td class="Botrule Rrule" align="center">1</td>
<td class="Botrule Rrule" align="center">2</td>
<td class="Botrule Rrule" align="center">0</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">        <span class="product-label-link" type="condition" conceptid="4098436" conceptname="Hyperkeratosis">Hyperkeratosis</span></td>
<td class="Botrule Rrule" align="center">7</td>
<td class="Botrule Rrule" align="center">0</td>
<td class="Botrule Rrule" align="center">0</td>
<td class="Botrule Rrule" align="center">0</td>
</tr>
<tr><td class="Botrule Lrule Rrule" align="left" colspan="5">   <span class="product-label-link" type="condition" conceptid="443784" conceptname="Vascular disorder">VASCULAR DISORDERS</span></td></tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">        <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span></td>
<td class="Botrule Rrule" align="center">33</td>
<td class="Botrule Rrule" align="center">8</td>
<td class="Botrule Rrule" align="center">4</td>
<td class="Botrule Rrule" align="center">0</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left">        <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span></td>
<td class="Botrule Rrule" align="center">7</td>
<td class="Botrule Rrule" align="center">1</td>
<td class="Botrule Rrule" align="center">0</td>
<td class="Botrule Rrule" align="center">0</td>
</tr>
</tbody>
</table>
<a name="t2"></a><table width="85%">
<caption><span>Table 2 Percent-Patient Incidence of Laboratory Abnormalities Occurring at a Higher Incidence in COMETRIQ-Treated Patients in Protocol XL184-301 [Between Arm Difference of ≥ 5% (All Grades) or ≥ 2% (Grades 3-4)]</span></caption>
<col align="left" valign="middle" width="50%">
<col align="center" valign="middle" width="12.5%">
<col align="center" valign="middle" width="12.5%">
<col align="center" valign="middle" width="12.5%">
<col align="center" valign="middle" width="12.5%">
<thead>
<tr class="First">
<th class="Botrule Lrule Rrule" align="left" valign="bottom">   Adverse Event</th>
<td class="Botrule Lrule Rrule" align="center" colspan="2">COMETRIQ<br> (n=214)</td>
<td class="Botrule Lrule Rrule" align="center" colspan="2">Placebo<br> (N=109)</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left"> </td>
<td class="Botrule Lrule Rrule" align="center">All<br> Grades</td>
<td class="Botrule Lrule Rrule" align="center">Grade<br> 3-4</td>
<td class="Botrule Lrule Rrule" align="center">All<br> Grades</td>
<td class="Botrule Lrule Rrule" align="center">Grade<br> 3-4</td>
</tr>
</thead>
<tbody>
<tr class="First">
<th class="Botrule Lrule Rrule" align="left">   Chemistries</th>
<td class="Botrule Lrule Rrule" align="center"></td>
<td class="Botrule Rrule" align="center"></td>
<td class="Botrule Rrule" align="center"></td>
<td class="Botrule Rrule" align="center"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">        Increased AST</td>
<td class="Botrule Rrule" align="center">86</td>
<td class="Botrule Rrule" align="center">3</td>
<td class="Botrule Rrule" align="center">35</td>
<td class="Botrule Rrule" align="center">2</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">        Increased ALT</td>
<td class="Botrule Rrule" align="center">86</td>
<td class="Botrule Rrule" align="center">6</td>
<td class="Botrule Rrule" align="center">41</td>
<td class="Botrule Rrule" align="center">2</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">        Increased ALP</td>
<td class="Botrule Rrule" align="center">52</td>
<td class="Botrule Rrule" align="center">3</td>
<td class="Botrule Rrule" align="center">35</td>
<td class="Botrule Rrule" align="center">3</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">        <span class="product-label-link" type="condition" conceptid="435510" conceptname="Hypocalcemia">Hypocalcemia</span></td>
<td class="Botrule Rrule" align="center">52</td>
<td class="Botrule Rrule" align="center">12</td>
<td class="Botrule Rrule" align="center">27</td>
<td class="Botrule Rrule" align="center">3</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">        <span class="product-label-link" type="condition" conceptid="4177973" conceptname="Hypophosphatemia">Hypophosphatemia</span></td>
<td class="Botrule Rrule" align="center">28</td>
<td class="Botrule Rrule" align="center">3</td>
<td class="Botrule Rrule" align="center">10</td>
<td class="Botrule Rrule" align="center">1</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">        <span class="product-label-link" type="condition" conceptid="4032334" conceptname="Hyperbilirubinemia">Hyperbilirubinemia</span></td>
<td class="Botrule Rrule" align="center">25</td>
<td class="Botrule Rrule" align="center">2</td>
<td class="Botrule Rrule" align="center">14</td>
<td class="Botrule Rrule" align="center">5</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">        <span class="product-label-link" type="condition" conceptid="4098604" conceptname="Hypomagnesemia">Hypomagnesemia</span></td>
<td class="Botrule Rrule" align="center">19</td>
<td class="Botrule Rrule" align="center">1</td>
<td class="Botrule Rrule" align="center">4</td>
<td class="Botrule Rrule" align="center">0</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">        <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">Hypokalemia</span></td>
<td class="Botrule Rrule" align="center">18</td>
<td class="Botrule Rrule" align="center">4</td>
<td class="Botrule Rrule" align="center">9</td>
<td class="Botrule Rrule" align="center">3</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">        <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">Hyponatremia</span></td>
<td class="Botrule Rrule" align="center">10</td>
<td class="Botrule Rrule" align="center">2</td>
<td class="Botrule Rrule" align="center">5</td>
<td class="Botrule Rrule" align="center">0</td>
</tr>
<tr>
<th class="Botrule Lrule Rrule" align="left">   Hematologic</th>
<td class="Botrule Lrule Rrule" align="center"></td>
<td class="Botrule Rrule" align="center"></td>
<td class="Botrule Rrule" align="center"></td>
<td class="Botrule Rrule" align="center"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">        <span class="product-label-link" type="condition" conceptid="441541" conceptname="Lymphocytopenia">Lymphopenia</span></td>
<td class="Botrule Rrule" align="center">53</td>
<td class="Botrule Rrule" align="center">16</td>
<td class="Botrule Rrule" align="center">51</td>
<td class="Botrule Rrule" align="center">11</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">        <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">Neutropenia</span></td>
<td class="Botrule Rrule" align="center">35</td>
<td class="Botrule Rrule" align="center">3</td>
<td class="Botrule Rrule" align="center">15</td>
<td class="Botrule Rrule" align="center">2</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">        <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">Thrombocytopenia</span></td>
<td class="Botrule Rrule" align="center">35</td>
<td class="Botrule Rrule" align="center">0</td>
<td class="Botrule Rrule" align="center">4</td>
<td class="Botrule Rrule" align="center">3</td>
</tr>
<tr><td class="Lrule Rrule" align="left" colspan="5"> </td></tr>
<tr class="Last"><td class="Botrule Lrule Rrule" align="left" colspan="5"><span class="Sup"> ALT, <span class="product-label-link" type="condition" conceptid="4211515" conceptname="Alanine aminotransferase">alanine aminotransferase</span>; ALP, alkaline phosphatase; AST, <span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">aspartate aminotransferase</span></span></td></tr>
</tbody>
</table>
<p>Nearly all COMETRIQ-treated patients (96% vs. 84% placebo) experienced elevated blood pressure and there was a doubling in the incidence of overt <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> in COMETRIQ-treated patients over placebo-treated patients (61% vs. 30%) according to modified Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC) staging criteria. No patients developed <span class="product-label-link" type="condition" conceptid="4289933" conceptname="Malignant hypertension">malignant hypertension</span>.</p>
<a name="t3"></a><table width="85%">
<caption><span>Table 3 Per-Patient Incidence of <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span> in Protocol XL184-301</span></caption>
<col align="left" valign="middle" width="75%">
<col align="center" valign="middle" width="12.5%">
<col align="center" valign="middle" width="12.5%">
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-6" href="#footnote-reference-6">*</a></dt>
<dd>Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure, JAMA 2003: 289:2560. Criteria applied were modified, as multiple readings were not available per timepoint, and therefore not averaged.</dd>
<dt><a name="footnote-7" href="#footnote-reference-7">†</a></dt>
<dd>Subjects classified by highest category based on all recorded blood pressure readings beginning after the first dose through 30 days after last dose.</dd>
<dt><a name="footnote-8" href="#footnote-reference-8">‡</a></dt>
<dd>Subjects with at least two blood pressure measurements after the first dose</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule" align="left">   <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span>, JNC<a name="footnote-reference-6" href="#footnote-6" class="Sup">*</a> Stage</td>
<td class="Botrule Lrule Rrule" align="center">COMETRIQ<br> N=211<a name="footnote-reference-7" href="#footnote-7" class="Sup">†</a>(%)</td>
<td class="Botrule Lrule Rrule" align="center">Placebo<br> N=107<a name="footnote-reference-8" href="#footnote-8" class="Sup">‡</a>(%)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">   Normal: Grade 0: Systolic &lt; 120 mmHg and Diastolic &lt; 80 mmHg</td>
<td class="Botrule Rrule" align="center">4</td>
<td class="Botrule Rrule" align="center">15</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">   Pre-<span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>: Systolic ≥ 120 mmHg or Diastolic ≥ 80 mmHg</td>
<td class="Botrule Rrule" align="center">34</td>
<td class="Botrule Rrule" align="center">54</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">   Stage 1: Systolic ≥ 140 mmHg or Diastolic ≥ 90 mmHg</td>
<td class="Botrule Rrule" align="center">46</td>
<td class="Botrule Rrule" align="center">25</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">   Stage 2: Systolic ≥ 160 mmHg or Diastolic ≥ 100 mmHg</td>
<td class="Botrule Rrule" align="center">15</td>
<td class="Botrule Rrule" align="center">5</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left">   Malignant: Diastolic ≥ 120 mmHg</td>
<td class="Botrule Rrule" align="center">0</td>
<td class="Botrule Rrule" align="center">0</td>
</tr>
</tbody>
</table>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="s7"></a><a name="section-7"></a><p></p>
<h1>7 DRUG INTERACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s7.1"></a><a name="section-7.1"></a><p></p>
<h2>7.1 Effect of CYP3A4 Inhibitors</h2>
<p class="First">Administration of a strong CYP3A4 inhibitor, ketoconazole (400 mg daily for 27 days) to healthy subjects increased single-dose plasma cabozantinib exposure (AUC<span class="Sub">0-inf</span>) by 38%. Avoid taking a strong CYP3A4 inhibitor (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconazole) when taking COMETRIQ <span class="Italics">[see <a href="#s2.1">Dosage and Administration</a> (<a href="#s2.1">2.1</a>) and <a href="#s5.10">Warnings and Precautions</a> (<a href="#s5.10">5.10</a>)].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s7.2"></a><a name="section-7.2"></a><p></p>
<h2>7.2 Effect of CYP3A4 Inducers</h2>
<p class="First">Administration of a strong CYP3A4 inducer, rifampin (600 mg daily for 31 days) to healthy subjects decreased single-dose plasma cabozantinib exposure (AUC<span class="Sub">0-inf</span>) by 77%. Avoid chronic co-administration of strong CYP3A4 inducers (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, rifapentine, phenobarbital, St. John’s Wort) with COMETRIQ <span class="Italics">[see <a href="#s2.1">Dosage and Administration</a> (<a href="#s2.1">2.1</a>) and <a href="#s5.10">Warnings and Precautions</a> (<a href="#s5.10">5.10</a>)].</span></p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="s8"></a><a name="section-8"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="s8.1"></a><a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<p class="First">Pregnancy Category D</p>
<p><span class="Italics">Risk Summary</span></p>
<p>Based on its mechanism of action, COMETRIQ can cause fetal harm when administered to a pregnant woman. Cabozantinib was embryolethal in rats at exposures below the recommended human dose, with increased incidences of skeletal variations in rats and visceral variations and malformations in rabbits. If this drug is used during pregnancy or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the fetus.</p>
<p><span class="Italics">Animal Data</span></p>
<p>In an embryo-fetal development study in which pregnant rats were administered daily doses of cabozantinib during organogenesis, increased loss of pregnancy compared to controls was observed at doses as low as 0.03 mg/kg (less than 1% of the human exposure by AUC at the recommended dose). Findings included delayed ossifications and skeletal variations at doses equal to or greater than 0.01 mg/kg/day (approximately 0.03% of the human exposure by AUC at the recommended dose).</p>
<p>In pregnant rabbits administered cabozantinib daily during organogenesis there were findings of visceral malformations and variations including reduced spleen size and missing lung lobe at 3 mg/kg (approximately 11% of the human exposure by AUC at the recommended dose).</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="s8.2"></a><a name="section-8.2"></a><p></p>
<h2>8.2 Nursing Mothers</h2>
<p class="First">It is unknown whether cabozantinib or its metabolites are excreted in human milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from COMETRIQ, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="s8.3"></a><a name="section-8.3"></a><p></p>
<h2>8.3 Pediatric Use</h2>
<p class="First">The safety and effectiveness of COMETRIQ in pediatric patients have not been studied.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="s8.4"></a><a name="section-8.4"></a><p></p>
<h2>8.4 Geriatric Use</h2>
<p class="First">Clinical studies of COMETRIQ did not include sufficient numbers of patients aged 65 years and
over to determine whether they respond differently from younger patients</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s8.5"></a><a name="section-8.5"></a><p></p>
<h2>8.5 Females and Males of Reproductive Potential</h2>
<p class="First"><span class="Italics">Contraception</span></p>
<p>Use effective contraception during treatment with COMETRIQ and up to 4 months after
completion of therapy.</p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="4035976" conceptname="Sterility">Infertility</span></span></p>
<p>There are no data on the effect of COMETRIQ on human fertility. Cabozantinib impaired male and female fertility in animal studies <span class="Italics">[see <a href="#s13.1">Nonclinical Toxicology</a> (<a href="#s13.1">13.1</a>)].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s8.6"></a><a name="section-8.6"></a><p></p>
<h2>8.6 <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></h2>
<p class="First">Cabozantinib pharmacokinetics has not been studied in patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>. There are limited data in patients with liver impairment (serum bilirubin greater than 1.5 times the upper limit of normal). COMETRIQ is not recommended for use in patients with moderate or severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>, as safety and efficacy have not been established <span class="Italics">[see <a href="#s2.1">Dosage and Administration</a> (<a href="#s2.1">2.1</a>) and <a href="#s5.11">Warnings and Precautions</a> (<a href="#s5.11">5.11</a>)].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s8.7"></a><a name="section-8.7"></a><p></p>
<h2>8.7 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></h2>
<p class="First">No dose adjustment is recommended for patients with mild or moderate <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. There
is no experience with COMETRIQ in patients with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="s10"></a><a name="section-9"></a><p></p>
<h1>10 OVERDOSAGE</h1>
<p class="First">One case of overdosage was reported in a patient who inadvertently took twice the intended dose (200 mg daily) for nine days. The patient suffered Grade 3 <span class="product-label-link" type="condition" conceptid="4304008" conceptname="Memory impairment">memory impairment</span>, Grade 3 <span class="product-label-link" type="condition" conceptid="436222" conceptname="Altered mental status">mental status changes</span>, Grade 3 cognitive disturbance, Grade 2 <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span>, and Grade 1 increase in BUN. The extent of recovery was not documented.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="s11"></a><a name="section-10"></a><p></p>
<h1>11 DESCRIPTION</h1>
<p class="First">COMETRIQ is the (<span class="Italics">S</span>)-malate salt of cabozantinib. Cabozantinib (<span class="Italics">S</span>)-malate is described chemically as <span class="Italics">N</span>-(4-(6,7-dimethoxyquinolin-4-yloxy)phenyl)-<span class="Italics">N'</span>-(4-fluorophenyl)cyclopropane- 1,1-dicarboxamide, (2<span class="Italics">S</span>)-hydroxybutanedioate. The molecular formula is C<span class="Sub">28</span>H<span class="Sub">24</span>FN<span class="Sub">3</span>O<span class="Sub">5</span>.C<span class="Sub">4</span>H<span class="Sub">6</span>O<span class="Sub">5</span> and the molecular weight is 635.6 Daltons as malate salt. The chemical structure of cabozantinib (<span class="Italics">S</span>)-malate salt is:</p>
<div class="Figure">
<a name="m1"></a><img alt="image of chemical structure of COMETRIQ" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=1a0c3bea-c87b-4d25-bb44-5f0174da6b34&amp;name=cometriq-chem-structure.jpg">
</div>
<p>Cabozantinib (<span class="Italics">S</span>)-malate salt is a white to off-white solid that is practically insoluble in aqueous
media.</p>
<p>COMETRIQ (cabozantinib) capsules are supplied as printed hard gelatin capsules containing cabozantinib (<span class="Italics">S</span>)-malate equivalent to 20 mg or 80 mg cabozantinib and the following inactive ingredients: silicified microcrystalline cellulose, croscarmellose sodium, sodium starch glycolate, fumed silica, and stearic acid.</p>
<p>The grey gelatin capsule shells contain black iron oxide and titanium dioxide and the Swedish orange gelatin capsule shells contain red iron oxide, and titanium dioxide. The printing ink contains shellac glaze, black iron oxide, <span class="Italics">N</span>-butyl alcohol, isopropyl alcohol, propylene glycol, and ammonium hydroxide.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="s12"></a><a name="section-11"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="s12.1"></a><a name="section-11.1"></a><p></p>
<h2>12.1 Mechanism of Action</h2>
<p class="First"><span class="Italics">In vitro</span> biochemical and/or cellular assays have shown that cabozantinib inhibits the tyrosine kinase activity of RET, MET, VEGFR-1, -2 and -3, KIT, TRKB, FLT-3, AXL, and TIE-2. These receptor tyrosine kinases are involved in both normal cellular function and pathologic processes such as oncogenesis, <span class="product-label-link" type="condition" conceptid="4147162" conceptname="Secondary malignant neoplasm of respiratory and digestive systems">metastasis</span>, tumor angiogenesis, and maintenance of the tumor microenvironment.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="s12.3"></a><a name="section-11.2"></a><p></p>
<h2>12.3 Pharmacokinetics</h2>
<p class="First">A population pharmacokinetic analysis of cabozantinib was performed using data collected from 289 patients with <span class="product-label-link" type="condition" conceptid="4030314" conceptname="Neoplasm">solid tumors</span> including MTC following oral administration of 140 mg daily doses. The predicted effective half-life is approximately 55 hours, the oral volume of distribution (V/F) is approximately 349 L, and the clearance (CL/F) at steady-state is estimated to be 4.4 L/hr.</p>
<p><span class="Italics">Absorption and Distribution</span></p>
<p>Following oral administration of COMETRIQ, median time to peak cabozantinib plasma concentrations (T<span class="Sub">max</span>) ranged from 2 to 5 hours post-dose. Repeat daily dosing of COMETRIQ at 140 mg for 19 days resulted in 4- to 5-fold mean cabozantinib accumulation (based on AUC) compared to a single dose administration; steady state was achieved by Day 15. Cabozantinib is highly protein bound in human plasma (≥ 99.7%).</p>
<p>A high-fat meal increased C<span class="Sub">max</span> and AUC values by 41% and 57%, respectively relative to fasted conditions in healthy subjects administered a single 140 mg oral COMETRIQ dose.</p>
<p><span class="Italics">Metabolism and Elimination</span></p>
<p>Cabozantinib is a substrate of CYP3A4 <span class="Italics">in vitro</span>. Inhibition of CYP3A4 reduced the formation of the XL184 <span class="Italics">N</span>-oxide metabolite by &gt;80%. Inhibition of CYP2C9 had a minimal effect on cabozantinib metabolite formation (i.e., a &lt;20% reduction). Inhibition of CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C19, CYP2D6 and CYP2E1 had no effect on cabozantinib metabolite formation.</p>
<p>Within a 48-day collection period after a single dose of <span class="Sup">14</span>C-cabozantinib in healthy subjects, approximately 81% of the total administered radioactivity was recovered with 54% in feces and 27% in urine.</p>
<p><span class="Italics">Specific Populations</span></p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span>:</span> No formal pharmacokinetic study of cabozantinib has been conducted in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. The results of a population pharmacokinetic analysis suggested that mild to moderate <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (creatinine clearance value ≥30 mL/min) does not have a
clinically relevant effect on the clearance of cabozantinib.</p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span>:</span> The pharmacokinetics of cabozantinib has not been studied in patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> [<span class="Italics">see <a href="#s2.1">Dosage and Administration</a> (<a href="#s2.1">2.1</a>) and <a href="#s5.11">Warnings and Precautions</a> (<a href="#s5.11">5.11</a>) and <a href="#s8.6">Use in Specific Populations</a> (<a href="#s8.6">8.6</a>)</span>].</p>
<p><span class="Italics">Pediatric Population:</span> The pharmacokinetics of cabozantinib has not been studied in the pediatric population <span class="Italics">[see <a href="#s8.3">Use in Specific Populations</a> (<a href="#s8.3">8.3</a>)].</span></p>
<p><span class="Italics">Effects of Age, Gender and Race:</span> A population PK analysis did not identify clinically relevant differences in clearance of cabozantinib between females and males or between Whites (89%) and non-Whites (11%). Cabozantinib pharmacokinetics was not affected by age (20-86 years).</p>
<p><span class="Italics">Drug Interactions</span></p>
<p><span class="Italics">CYP Enzyme Inhibition and Induction:</span> Cabozantinib is a noncompetitive inhibitor of CYP2C8 (Ki<span class="Sub">app</span> = 4.6 μM), a mixed-type inhibitor of both CYP2C9 (Ki<span class="Sub">app</span> = 10.4 μM) and CYP2C19 (Ki<span class="Sub">app</span> = 28.8 μM), and a weak competitive inhibitor of CYP3A4 (estimated Ki<span class="Sub">app</span> = 282 μM) in human liver microsomal (HLM) preparations. IC<span class="Sub">50</span> values &gt;20 μM were observed for CYP1A2, CYP2D6, and CYP3A4 isozymes in both recombinant and HLM assay systems.</p>
<p>Cabozantinib is an inducer of CYP1A1 mRNA in human hepatocyte incubations (i.e., 75-100% of CYP1A1 positive control β-naphthoflavone induction), but not of CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19 or CYP3A4 mRNA or isozyme-associated enzyme activities.</p>
<p>Cabozantinib at steady-state plasma concentrations (≥100 mg/day daily for a minimum of 21 days) showed no effect on single-dose rosiglitazone (a CYP2C8 substrate) plasma exposure (C<span class="Sub">max</span> and AUC) in patients with <span class="product-label-link" type="condition" conceptid="4030314" conceptname="Neoplasm">solid tumors</span>.</p>
<p><span class="Italics">P-glycoprotein Inhibition:</span> Cabozantinib is an inhibitor (IC<span class="Sub">50</span> = 7.0 μM), but not a substrate, of P-gp transport activities in a bi-directional assay system using MDCK-MDR1 cells. Therefore, cabozantinib may have the potential to increase plasma concentrations of co-administered substrates of P-gp.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s12.6"></a><a name="section-11.3"></a><p></p>
<h2>12.6 Cardiac Electrophysiology</h2>
<p class="First">The effect of orally administered COMETRIQ 140 mg on QTc interval was evaluated in a randomized, double-blinded, placebo-controlled study in patients with MTC. A mean increase in QTcF of 10 - 15 ms was observed at 4 weeks after initiating COMETRIQ. A concentration-QTc relationship could not be definitively established. Changes in cardiac wave form morphology or new rhythms were not observed. No COMETRIQ-treated patients had a QTcF &gt; 500 ms <span class="Italics">[see <a href="#s14">Clinical Studies</a> (<a href="#s14">14</a>)].</span></p>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="s13"></a><a name="section-12"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="s13.1"></a><a name="section-12.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">Studies examining the carcinogenic potential of cabozantinib have not been conducted.</p>
<p>Cabozantinib was not mutagenic <span class="Italics">in vitro</span> in the bacterial reverse mutation (Ames) assay and was not clastogenic in both the <span class="Italics">in vitro</span> cytogenetic assay using human <span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span> or in the <span class="Italics">in vivo</span> mouse micronucleus assay.</p>
<p>Based on nonclinical findings, male and female fertility may be impaired by treatment with COMETRIQ. In a fertility study in which cabozantinib was administered to male and female rats at doses of 1, 2.5, and 5 mg/kg/day, male fertility was significantly compromised at doses equal to or greater than 2.5 mg/kg/day (approximately equal to the human exposure by AUC at the recommended dose), with a decrease in sperm counts and reproductive organ weights. In females, fertility was significantly reduced at doses equal to or greater than 1 mg/kg/day (approximately 50% of the human exposure by AUC at the recommended dose) with a significant decrease in the number of live embryos and a significant increase in pre- and postimplantation losses.</p>
<p>Observations of effects on reproductive tract tissues in general toxicology studies were supportive of effects noted in the dedicated fertility study and included hypospermia and absence of corpora lutea in male and female dogs in a 6-month repeat dose study at exposures equal to 6% and 3%, respectively, the human exposure by AUC at the recommended dose. In addition, female rats administered 5 mg/kg/day for 14 days (approximately equal to the human exposure by AUC at the recommended dose) exhibited ovarian <span class="product-label-link" type="condition" conceptid="4280654" conceptname="Necrosis">necrosis</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="s14"></a><a name="section-13"></a><p></p>
<h1>14 CLINICAL STUDIES</h1>
<p class="First">The safety and efficacy of COMETRIQ was assessed in an international, multi-center, randomized, double-blind, controlled trial (Study 1) of 330 patients with metastatic medullary thyroid carcinoma (MTC). Patients were required to have evidence of actively progressive disease within 14 months prior to study entry confirmed by an Independent Radiology Review Committee (IRRC) masked to treatment assignment (89%) or the treating physician (11%). Patients were randomized (2:1) to receive COMETRIQ 140 mg (n = 219) or placebo (n = 111) orally once daily, without food, until disease progression determined by the treating physician or until intolerable toxicity. Randomization was stratified by age (≤ 65 years vs. &gt; 65 years) and prior use of a tyrosine kinase inhibitor (TKI) (yes vs. no). No cross-over was allowed at the time of progression. The main efficacy outcome measures of progression-free survival (PFS), objective response (OR), and response duration were based on IRRC-confirmed events using modified RECIST criteria.</p>
<p>Of 330 patients randomized, 67% were male, the median age was 55 years, 23% were 65 years or older, 89% were white, 54% had a baseline ECOG performance status of 0, 92% had undergone a thyroidectomy, and 48% were reported to be <span class="Italics">RET</span> mutation positive according to research-use assays. Twenty-five percent (25%) had two or more prior systemic therapies and 21% had been previously treated with a TKI.</p>
<p>A statistically significant prolongation in PFS was demonstrated among COMETRIQ-treated patients compared to those receiving placebo [HR 0.28 (95% CI: 0.19, 0.40); p &lt;0.0001], with median PFS times of 11.2 months and 4.0 months in the COMETRIQ and placebo arms, respectively.</p>
<p>Partial responses were observed only among patients in the COMETRIQ arm (27% vs. 0; p&lt;0.0001). The median duration of objective responses was 14.7 months (95% CI: 11.1, 19.3) for patients treated with COMETRIQ. There was no statistically significant difference in overall survival between the treatment arms at the planned interim analysis.</p>
<br><p><span class="Bold">Figure 1: Progression-Free Survival</span></p>
<div class="Figure">
<a name="m2"></a><img alt="image of progression-free survival" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=1a0c3bea-c87b-4d25-bb44-5f0174da6b34&amp;name=cometriq-figure-01.jpg">
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="s16"></a><a name="section-14"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING</h1>
<p class="First">COMETRIQ 20 mg capsules are supplied as hard gelatin capsules with grey cap and grey body, printed with "XL184 20mg" in black ink and containing cabozantinib (<span class="Italics">S</span>)-malate salt equivalent to 20 mg cabozantinib.</p>
<p>COMETRIQ 80 mg capsules are supplied as hard gelatin capsules with Swedish orange cap and Swedish orange body, printed with "XL184 80mg" in black ink and containing cabozantinib (<span class="Italics">S</span>)- malate salt equivalent to 80 mg cabozantinib.</p>
<p>COMETRIQ capsules are supplied as follows:<br>Cartons</p>
<ul>
<li>140 mg daily-dose carton                                                                  NDC#42388-011-14<br>Containing four 140 mg daily-dose <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> cards<br>(each <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> card contains seven 80-mg and twenty-one 20-mg capsules)</li>
<li>100 mg daily-dose carton                                                                  NDC#42388-012-14<br>Containing four 100 mg daily-dose <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> cards<br>(each <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> card contains seven 80-mg and seven 20-mg capsules)</li>
<li>60 mg daily-dose carton                                                                    NDC#42388-013-14<br>Containing four 60 mg daily-dose <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> cards<br>(each <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> card contains twenty-one 20-mg capsules)</li>
</ul>
<p>Bottle containing sixty 20-mg COMETRIQ capsules                                NDC#42388-014-25</p>
<p>Store COMETRIQ at 20°C to 25°C (68°F to 77°F); excursions are permitted from 15°C to 30°C (59°F to 86°F) [see USP Controlled Room Temperature].</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="s17"></a><a name="section-15"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION</h1>
<p class="First">See <a href="#ppi1">FDA-approved patient labeling</a> (<a href="#ppi1">Patient Information and Instructions for Use</a>).</p>
<p>Inform patients of the following:</p>
<ul>
<li>COMETRIQ often causes <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> which may be severe in some cases. Inform patients of the need to contact their healthcare provider if severe <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> occurs during treatment with COMETRIQ.</li>
<li>COMETRIQ often causes palmar plantar erythrodysesthesia syndrome. Advise patients to contact their healthcare provider for progressive or intolerable <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>.</li>
<li>COMETRIQ often causes sores in the mouth, <span class="product-label-link" type="condition" conceptid="4010025" conceptname="Painful mouth">oral pain</span>, changes in taste, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> or <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>. Advise patients to contact their healthcare provider if any of these symptoms are severe or prevent patients from eating and drinking.</li>
<li>COMETRIQ often causes <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span> which may be significant in some cases. Advise patients to report significant <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span>.</li>
<li>To contact their healthcare provider before any planned surgeries, including dental procedures.</li>
<li>COMETRIQ may interact with other drugs; advise patients to inform their healthcare provider of all prescription or nonprescription medication or herbal products that they are taking.</li>
<li>Patients of childbearing potential must use effective contraception during therapy and for at least four months following their last dose of COMETRIQ.</li>
<li>Breast-feeding mothers must discontinue nursing while receiving COMETRIQ therapy.</li>
<li>COMETRIQ should <span class="Bold">not</span> be taken with food. Instruct patients not to eat for at least 2 hours before and at least 1 hour after taking COMETRIQ. COMETRIQ capsules should not be opened or crushed but should be taken with a full glass (at least 8 ounces) of water.</li>
<li>Patients should <span class="Bold">not</span> consume grapefruits or grapefruit juice while taking COMETRIQ treatment.</li>
</ul>
<p>Manufactured for: Exelixis, Inc.</p>
<br><br><br>
</div>
<div class="Section" data-sectionCode="42230-3">
<a name="ppi1"></a><a name="section-16"></a><p></p>
<p class="First"><span class="Bold">PATIENT INFORMATION<br>COMETRIQ<span class="Sup">™</span> (Ko-me-trik)<br>cabozantinib<br> capsules</span></p>
<p><span class="Bold">What is the most important information I should know about COMETRIQ?</span></p>
<p><span class="Bold">COMETRIQ can cause serious side effects which can lead to <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>, including:</span></p>
<p><span class="Bold">Severe <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> (<span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span>).</span> Tell your healthcare provider right away if you get any signs of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> while taking or after you stop taking COMETRIQ, including:</p>
<ul>
<li><span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">coughing</span> up blood or blood clots</li>
<li><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> blood or if your vomit looks like coffee-grounds</li>
<li>red or black (looks like tar) stools</li>
<li>menstrual <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> that is heavier than normal</li>
<li>any unusual or heavy <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span></li>
</ul>
<p><span class="Bold">A tear in your stomach or intestinal wall (perforation), or an abnormal connection between 2 parts of your body (<span class="product-label-link" type="condition" conceptid="4043006" conceptname="Fistula">fistula</span>).</span> Tell your healthcare provider right away if you get:</p>
<ul>
<li>severe <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> in your stomach-area (abdomen)</li>
<li><span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">coughing</span>, <span class="product-label-link" type="condition" conceptid="4091505" conceptname="Gagging">gagging</span>, and <span class="product-label-link" type="condition" conceptid="4096712" conceptname="Choking">choking</span> especially when eating or drinking</li>
</ul>
<p><span class="Bold">What is COMETRIQ?</span></p>
<p>COMETRIQ is a prescription medicine used to treat people with medullary thyroid
cancer that has spread to other parts of the body.</p>
<p>It is not known if COMETRIQ is safe and effective in children.</p>
<p><span class="Bold">What should I tell my healthcare provider before taking COMETRIQ?</span></p>
<p>Before you take COMETRIQ, tell your healthcare provider if you:</p>
<ul>
<li>have high blood pressure</li>
<li>have a recent history of <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">coughing</span> up blood or <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> or any unusual <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span></li>
<li>have an open <span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">wound</span></li>
<li>have had recent surgery or plan to have surgery or a dental procedure</li>
<li>have liver problems</li>
<li>have any other medical conditions</li>
<li>are pregnant or you or your partner plan to become pregnant. COMETRIQ can cause harm to your unborn baby. Talk to your healthcare provider if you are pregnant or if you or your partner plan to become pregnant.</li>
<li>are a female who is able to become pregnant, or are a male whose female partner is able to become pregnant; you should use effective birth control during your treatment with COMETRIQ and for at least 4 months after your last dose of COMETRIQ.<br>     ο  Talk to your healthcare provider about birth control methods to prevent pregnancy while you are taking COMETRIQ.<br>     ο  Tell your healthcare provider right away if you or your female partner becomes pregnant while taking COMETRIQ.</li>
<li>are breastfeeding or plan to breastfeed. It is not known if COMETRIQ passes into your breast milk. You and your healthcare provider should decide if you will take COMETRIQ or breastfeed. You should not do both.</li>
</ul>
<p><span class="Bold">Tell your healthcare provider about all the medicines you take,</span> including prescription or over-the-counter medicines, vitamins, and herbal supplements. COMETRIQ and certain other medicines may affect each other causing side effects.</p>
<p>Know the medicines you take. Keep a list of them to show your healthcare provider and pharmacist when you get a new medicine.</p>
<p><span class="Bold">How should I take COMETRIQ?</span></p>
<ul>
<li>Take COMETRIQ exactly as your healthcare provider tells you to take it.</li>
<li>Take COMETRIQ on an empty stomach, do not eat for at least 2 hours before and at least 1 hour after taking COMETRIQ.</li>
<li>Swallow COMETRIQ capsules whole with at least 8 ounces of water. Do not crush or open COMETRIQ capsules.</li>
<li>If you miss a dose and your next dose is in:<br>     ο  less than 12 hours, take your next dose at the normal time. Do not make up the missed dose.<br>     ο  12 hours or more, take the missed dose as soon as you remember. Take your next dose at the normal time.</li>
<li>Call your healthcare provider right away if you take too much COMETRIQ.</li>
</ul>
<p><span class="Bold">What should I avoid while taking COMETRIQ?</span></p>
<p>You should not drink grapefruit juice, eat grapefruit or any foods or supplements
that contain these products, during treatment with COMETRIQ. They may increase
the amount of COMETRIQ in your blood.</p>
<p><span class="Bold">What are the possible side effects of COMETRIQ?</span></p>
<p><span class="Bold">COMETRIQ may cause serious side effects, including:</span></p>
<p><span class="Bold"></span></p>
<p></p>
<p></p>
<ul><li>
<span class="Bold">See "What is the most important information I should know about COMETRIQ?"<br>     •  blood clots, <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attack</span>, and <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>.</span> Get emergency help right away if you get:<br>       • <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> or <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> in your arms or legs<br>       • <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span><br>       • feel lightheaded or <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">faint</span><br>       • <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span> more than usual<br>       • <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">numbness</span> or <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span> of your face, arm or leg, especially on one side of your body<br>       • sudden <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, trouble speaking or understanding<br>       • sudden trouble seeing in one or both eyes<br>       • sudden trouble walking<br>       • <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, loss of balance or coordination<br>       • a sudden severe <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span><br>     • <span class="Bold"><span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">wound</span> healing problems.</span> If you need to have surgery, tell your healthcare provider that you are taking COMETRIQ. Your healthcare provider should stop your treatment with COMETRIQ at least 28 days before any planned surgery, including dental procedures. Your healthcare provider should tell you when you may start taking COMETRIQ again after surgery.<br>     • h<span class="Bold">igh blood pressure (<span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>) which may be severe.</span> Your healthcare provider should check your blood pressure during treatment with COMETRIQ. If needed, your healthcare provider should prescribe medicine for you to treat high blood pressure.<br>     • <span class="Bold">severe jaw bone problems (<span class="product-label-link" type="condition" conceptid="77650" conceptname="Aseptic necrosis of bone">osteonecrosis</span>).</span> Symptoms may include: <span class="product-label-link" type="condition" conceptid="4168686" conceptname="Jaw pain">jaw pain</span>, <span class="product-label-link" type="condition" conceptid="4099176" conceptname="Toothache">toothache</span>, or sores on your gums. Your healthcare provider should examine your mouth before you start and during treatment with COMETRIQ. Tell your dentist that you are taking COMETRIQ. It is important for you to practice good mouth care during treatment with COMETRIQ.<br>     • <span class="Bold">a skin problem called hand-foot <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reaction</span>.</span> Symptoms may include: <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">redness</span>, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span>, or <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blisters</span> on the palms of your hands or soles of your feet.<br>     • <span class="Bold">protein in your urine and possible kidney problems.</span> Symptoms may include: <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> in your hands, arms, legs or feet.<br>     • <span class="Bold"><span class="product-label-link" type="condition" conceptid="42872891" conceptname="Posterior reversible encephalopathy syndrome">Reversible Posterior Leukoencephalopathy Syndrome</span> (RPLS).</span> A condition called <span class="product-label-link" type="condition" conceptid="42872891" conceptname="Posterior reversible encephalopathy syndrome">reversible posterior leukoencephalopathy syndrome</span> can happen while taking COMETRIQ. Call your healthcare provider right away if you have <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headaches</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, changes in vision, or problems thinking.</li></ul>
<p><span class="Bold">Your healthcare provider may tell you to stop taking COMETRIQ if you have any of the serious side effects listed above.</span></p>
<p>The most common side effects of COMETRIQ are:</p>
<ul>
<li><span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">redness</span>, <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> or <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> in your mouth or throat, or mouth sores</li>
<li><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span></li>
<li><span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span></li>
<li><span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">decreased appetite</span></li>
<li><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span></li>
<li><span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">tiredness</span> and <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span></li>
<li>change in taste</li>
<li>hair color turning lighter</li>
<li><span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span></li>
<li>voice changes or <span class="product-label-link" type="condition" conceptid="4142495" conceptname="Hypophonia">hoarseness</span></li>
<li>change in liver function blood tests</li>
<li>low levels of calcium in your blood</li>
</ul>
<p>Tell your healthcare provider if you have any side effect that bothers you or that does not go away.</p>
<p>These are not all the possible side effects of COMETRIQ. For more information, ask your healthcare provider or pharmacist.</p>
<p>Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.</p>
<p><span class="Bold">How should I store COMETRIQ?</span></p>
<ul><li>Store COMETRIQ at room temperature 68°F to 77°F (20°C to 25°C).</li></ul>
<p><span class="Bold">Keep COMETRIQ and all medicines out of the reach of children.</span></p>
<p><span class="Bold">General information about COMETRIQ.</span></p>
<p>Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use COMETRIQ for a condition for which it was not prescribed. Do not give COMETRIQ to other people, even if they have the same symptoms you have. It may harm them.</p>
<p>You can ask your healthcare provider or pharmacist for information about COMETRIQ that is written for health professionals.</p>
<p>For more information, go to www.cometriq.com or call 1-855-292-3935.</p>
<p><span class="Bold">What are the ingredients in COMETRIQ?</span></p>
<p>Active ingredient: cabozantinib (<span class="Italics">S</span>)-malate<br>Inactive ingredients:</p>
<ul>
<li>
<span class="Bold">Capsule contents:</span> silicified microcrystalline cellulose, croscarmellose sodium, sodium starch glycolate, fumed silica, and stearic acid</li>
<li>
<span class="Bold">Capsule shells:</span><br>     • Grey gelatin capsules: black iron oxide and titanium dioxide<br>     • Swedish orange gelatin capsules: red iron oxide and titanium dioxide</li>
<li>
<span class="Bold">Printing ink:</span> shellac glaze, black iron oxide, <span class="Italics">N</span>-butyl alcohol, isopropyl
alcohol, propylene glycol, and ammonium hydroxide</li>
</ul>
<p>This Patient Information has been approved by the U.S. Food and Drug Administration.</p>
<p>Manufactured for: Exelixis, Inc.</p>
<p>11/2012</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="p1"></a><a name="section-17"></a><p></p>
<p class="First"><br><span class="Bold">Package Label - CARTON - 140 mg Daily Dose of COMETRIQ</span></p>
<p><span class="Bold">PRINCIPAL DISPLAY PANEL</span><br><br></p>
<p><span class="Bold">Cometriq<span class="Sup">™</span><br>(cabozantinib) capsules<br><br>140 mg Daily Dose<br> <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">Blister</span> Cards</span><br><br>Each 140 mg daily dose contains a combination of<br> one Swedish orange 80 mg and three grey 20 mg<br>
capsules. Each capsule contains cabozantinib<br> (<span class="Italics">S</span>)-malate equivalent to 80 mg or 20 mg of<br>
cabozantinib. <br><br><span class="Bold">EXELIXIS<span class="Sup">®</span><br><br> NDC 42388-011-14<br><br>Carton containing 4 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> cards:<br> The <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> cards in this carton are for<br> patients prescribed a 140 mg daily dose.<br><br>Rx Only</span><br><br></p>
<div class="Figure">
<a name="m4"></a><img alt="carton - 140 mg daily dose of COMETRIQ" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=1a0c3bea-c87b-4d25-bb44-5f0174da6b34&amp;name=cometriq-140mg-carton.jpg">
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="p2"></a><a name="section-18"></a><p></p>
<p class="First"><br><span class="Bold">Package Label - CARTON - 100 mg Daily Dose of COMETRIQ</span></p>
<p><span class="Bold">PRINCIPAL DISPLAY PANEL</span><br><br></p>
<p><span class="Bold">Cometriq<span class="Sup">™</span><br>(cabozantinib) capsules<br><br>100 mg Daily Dose<br> <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">Blister</span> Cards</span><br><br>Each 100 mg daily dose contains a combination<br> of one Swedish orange 80 mg and one grey<br> 20 mg capsule. Each capsule contains<br> cabozantinib (<span class="Italics">S</span>)-malate equivalent to 80 mg<br> or 20 mg of cabozantinib.<br><br><span class="Bold">EXELIXIS<span class="Sup">®</span><br><br>NDC 42388-012-14<br><br>Carton containing 4 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> cards:<br> The <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> cards in this carton are for<br> patients prescribed a 100 mg daily dose.<br><br>Rx Only</span><br><br></p>
<div class="Figure">
<a name="m5"></a><img alt="carton - 100 mg daily dose of COMETRIQ" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=1a0c3bea-c87b-4d25-bb44-5f0174da6b34&amp;name=cometriq-100mg-carton.jpg">
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="p3"></a><a name="section-19"></a><p></p>
<p class="First"><br><span class="Bold">Package Label - CARTON - 60 mg Daily Dose of COMETRIQ</span></p>
<p><span class="Bold">PRINCIPAL DISPLAY PANEL</span><br><br></p>
<p><span class="Bold">Cometriq<span class="Sup">™</span><br>(cabozantinib) capsules<br><br>60 mg Daily Dose<br> <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">Blister</span> Cards</span><br><br>Each 60 mg daily dose contains three grey 20 mg<br> capsules. Each capsule contains cabozantinib<br>(<span class="Italics">S</span>)-malate equivalent to 20 mg of cabozantinib.<br><br><span class="Bold">EXELIXIS<span class="Sup">®</span><br><br>NDC 42388-013-14<br><br>Carton containing 4 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> cards:<br> The <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> cards in this carton are for<br> patients prescribed a 60 mg daily dose.<br><br>Rx Only</span><br><br></p>
<div class="Figure">
<a name="m6"></a><img alt="carton - 60 mg daily dose of COMETRIQ" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=1a0c3bea-c87b-4d25-bb44-5f0174da6b34&amp;name=cometriq-60mg-carton.jpg">
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="p4"></a><a name="section-20"></a><p></p>
<p class="First"><span class="Bold">Package Label - Bottle - 60 Count</span></p>
<p><span class="Bold">PRINCIPAL DISPLAY PANEL</span><br><br></p>
<p><span class="Bold">Cometriq<span class="Sup">™</span><br>(cabozantinib) capsules<br><br>20 mg*</span><br><br> Rx Only<br><br><span class="Bold">60 Capsules<br><br>EXELIXIS<span class="Sup">®</span><br><br>NDC 42388-014-25</span><br><br></p>
<div class="Figure">
<a name="m7"></a><img alt="label - bottle - 60 ct - 20 mg" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=1a0c3bea-c87b-4d25-bb44-5f0174da6b34&amp;name=cometriq-bottle-60-ct-label.jpg">
</div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>COMETRIQ 		
					</strong><br><span class="contentTableReg">cabozantinib kit</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:42388-011</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:42388-011-14</td>
<td class="formItem">4  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">1  in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Quantity of Parts</td></tr>
<tr>
<th scope="col" width="5" class="formTitle">Part #</th>
<th scope="col" class="formTitle">Package Quantity</th>
<th scope="col" class="formTitle">Total Product Quantity</th>
</tr>
<tr class="formTableRowAlt">
<td width="5" class="formItem"><strong>Part 1</strong></td>
<td class="formItem"> </td>
<td class="formItem">7 </td>
</tr>
<tr class="formTableRow">
<td width="5" class="formItem"><strong>Part 2</strong></td>
<td class="formItem"> </td>
<td class="formItem">21 </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellspacing="0" cellpadding="5">
<tr><td class="contentTableTitle">Part 1 of 2</td></tr>
<tr><td class="contentTableTitle">
<strong>COMETRIQ 		
					</strong><br><span class="contentTableReg">cabozantinib capsule</span>
</td></tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt"></tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">oral</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>cabozantinib s-malate</strong> (cabozantinib) </td>
<td class="formItem">cabozantinib</td>
<td class="formItem">80 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>cellulose, microcrystalline</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>croscarmellose sodium</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>sodium starch glycolate type a potato</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>silicon dioxide</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>stearic acid</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>gelatin</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ferric oxide red</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>ferrosoferric oxide</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>titanium dioxide</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>shellac</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>butyl alcohol</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>isopropyl alcohol</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>propylene glycol</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong><span class="product-label-link" type="condition" conceptid="4184927" conceptname="Ammonia">ammonia</span></strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">orange (Swedish Orange) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">capsule</td>
<td class="formLabel">Size</td>
<td class="formItem">19mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">XL184;80mg</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA203756</td>
<td class="formItem">11/29/2012</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellspacing="0" cellpadding="5">
<tr><td class="contentTableTitle">Part 2 of 2</td></tr>
<tr><td class="contentTableTitle">
<strong>COMETRIQ 		
					</strong><br><span class="contentTableReg">cabozantinib capsule</span>
</td></tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt"></tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">oral</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>cabozantinib s-malate</strong> (cabozantinib) </td>
<td class="formItem">cabozantinib</td>
<td class="formItem">20 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>cellulose, microcrystalline</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>croscarmellose sodium</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>sodium starch glycolate type a potato</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>silicon dioxide</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>stearic acid</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>gelatin</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ferrosoferric oxide</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>titanium dioxide</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>shellac</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>butyl alcohol</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>isopropyl alcohol</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>propylene glycol</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong><span class="product-label-link" type="condition" conceptid="4184927" conceptname="Ammonia">ammonia</span></strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">gray</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">capsule</td>
<td class="formLabel">Size</td>
<td class="formItem">19mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">XL184;20mg</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA203756</td>
<td class="formItem">11/29/2012</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA203756</td>
<td class="formItem">11/29/2012</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>COMETRIQ 		
					</strong><br><span class="contentTableReg">cabozantinib kit</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:42388-012</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:42388-012-14</td>
<td class="formItem">4  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">1  in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Quantity of Parts</td></tr>
<tr>
<th scope="col" width="5" class="formTitle">Part #</th>
<th scope="col" class="formTitle">Package Quantity</th>
<th scope="col" class="formTitle">Total Product Quantity</th>
</tr>
<tr class="formTableRowAlt">
<td width="5" class="formItem"><strong>Part 1</strong></td>
<td class="formItem"> </td>
<td class="formItem">7 </td>
</tr>
<tr class="formTableRow">
<td width="5" class="formItem"><strong>Part 2</strong></td>
<td class="formItem"> </td>
<td class="formItem">7 </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellspacing="0" cellpadding="5">
<tr><td class="contentTableTitle">Part 1 of 2</td></tr>
<tr><td class="contentTableTitle">
<strong>COMETRIQ 		
					</strong><br><span class="contentTableReg">cabozantinib capsule</span>
</td></tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt"></tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">oral</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>cabozantinib s-malate</strong> (cabozantinib) </td>
<td class="formItem">cabozantinib</td>
<td class="formItem">80 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>cellulose, microcrystalline</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>croscarmellose sodium</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>sodium starch glycolate type a potato</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>silicon dioxide</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>stearic acid</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>gelatin</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ferric oxide red</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>ferrosoferric oxide</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>titanium dioxide</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>shellac</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>butyl alcohol</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>isopropyl alcohol</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>propylene glycol</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong><span class="product-label-link" type="condition" conceptid="4184927" conceptname="Ammonia">ammonia</span></strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">orange (Swedish Orange) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">capsule</td>
<td class="formLabel">Size</td>
<td class="formItem">19mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">XL184;80mg</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA203756</td>
<td class="formItem">11/29/2012</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellspacing="0" cellpadding="5">
<tr><td class="contentTableTitle">Part 2 of 2</td></tr>
<tr><td class="contentTableTitle">
<strong>COMETRIQ 		
					</strong><br><span class="contentTableReg">cabozantinib capsule</span>
</td></tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt"></tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">oral</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>cabozantinib s-malate</strong> (cabozantinib) </td>
<td class="formItem">cabozantinib</td>
<td class="formItem">20 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>cellulose, microcrystalline</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>croscarmellose sodium</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>sodium starch glycolate type a potato</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>silicon dioxide</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>stearic acid</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>gelatin</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ferrosoferric oxide</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>titanium dioxide</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>shellac</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>butyl alcohol</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>isopropyl alcohol</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>propylene glycol</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong><span class="product-label-link" type="condition" conceptid="4184927" conceptname="Ammonia">ammonia</span></strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">gray</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">capsule</td>
<td class="formLabel">Size</td>
<td class="formItem">19mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">XL184;20mg</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA203756</td>
<td class="formItem">11/29/2012</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA203756</td>
<td class="formItem">11/29/2012</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>COMETRIQ 		
					</strong><br><span class="contentTableReg">cabozantinib capsule</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:42388-013</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">oral</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>cabozantinib s-malate</strong> (cabozantinib) </td>
<td class="formItem">cabozantinib</td>
<td class="formItem">20 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>cellulose, microcrystalline</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>croscarmellose sodium</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>sodium starch glycolate type a potato</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>silicon dioxide</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>stearic acid</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>gelatin</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ferrosoferric oxide</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>titanium dioxide</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>shellac</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>butyl alcohol</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>isopropyl alcohol</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>propylene glycol</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong><span class="product-label-link" type="condition" conceptid="4184927" conceptname="Ammonia">ammonia</span></strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">gray</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">capsule</td>
<td class="formLabel">Size</td>
<td class="formItem">19mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">XL184;20mg</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:42388-013-14</td>
<td class="formItem">4  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">21  in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA203756</td>
<td class="formItem">11/29/2012</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>COMETRIQ 		
					</strong><br><span class="contentTableReg">cabozantinib capsule</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:42388-014</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">oral</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>cabozantinib s-malate</strong> (cabozantinib) </td>
<td class="formItem">cabozantinib</td>
<td class="formItem">20 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>cellulose, microcrystalline</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>croscarmellose sodium</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>sodium starch glycolate type a potato</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>silicon dioxide</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>stearic acid</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>gelatin</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ferrosoferric oxide</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>titanium dioxide</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>shellac</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>butyl alcohol</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>isopropyl alcohol</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>propylene glycol</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong><span class="product-label-link" type="condition" conceptid="4184927" conceptname="Ammonia">ammonia</span></strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">gray</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">capsule</td>
<td class="formLabel">Size</td>
<td class="formItem">19mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">XL184;20mg</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:42388-014-25</td>
<td class="formItem">60  in 1 bottle</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA203756</td>
<td class="formItem">11/29/2012</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Exelixis, Inc.
							(785991949)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Catalent Pharma Solutions, Inc.</td>
<td class="formItem"></td>
<td class="formItem">962674474</td>
<td class="formItem">MANUFACTURE(42388-011, 42388-012, 42388-013, 42388-014)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 12/2012<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>0c07e5b3-aece-49e8-bbb4-84ee29f58661</div>
<div>Set id: 1a0c3bea-c87b-4d25-bb44-5f0174da6b34</div>
<div>Version: 2</div>
<div>Effective Time: 20121204</div>
</div>
</div> <div class="DistributorName">Exelixis, Inc.</div></p>
</body></html>
